Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astellas Pharma's Other Operating Expense for the
three
months ended in Jun. 2026 was 円36,062 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was 円161,955 Mil.
Astellas Pharma's quarterly Other Operating Expense
increased
from Dec. 2025 (円24,889 Mil) to Mar. 2026 (円65,051 Mil) but then
declined
from Mar. 2026 (円65,051 Mil) to Jun. 2026 (円36,062 Mil).
Astellas Pharma's annual Other Operating Expense
increased
from Mar. 2024 (円257,943 Mil) to Mar. 2025 (円352,186 Mil) but then
declined
from Mar. 2025 (円352,186 Mil) to Mar. 2026 (円175,622 Mil).
Astellas Pharma Other Operating Expense Related Terms
Astellas Pharma Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円161,955 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of 円161,955 Mil mean?
Astellas Pharma (TSE:4503) has a Other Operating Expense of 円161,955 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Other Operating Expense too high?
Astellas Pharma's current Other Operating Expense is 円161,955 Mil. Overall, Astellas Pharma has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Other Operating Expense compare to LLY and JNJ?
Astellas Pharma's Other Operating Expense of 円161,955 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Other Operating Expense is 円161,955 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (TSE:4503) is currently considered Fairly Valued. The stock's GF Value™ is 円2,306.53, compared to a current price of 円2,356.00 — trading 2.1% above its estimated fair value. The current Other Operating Expense is 円161,955 Mil. Astellas Pharma's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Astellas Pharma (TSE:4503), the current Other Operating Expense is 円161,955 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (TSE:4503) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued.
The current stock price of 円2,356.00 is trading 2.1% above its estimated GF Value™ of 円2,306.53.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for TSE:4503:
Other Operating Expense: 円161,955 Mil
GF Value™: 円2,306.53 vs. price of 円2,356.00 (2.1% above fair value)
No single metric tells the full story. See the TSE:4503 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
82GF Score
Get the complete analysis for TSE:4503
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4503 has been successfully added to your 
